Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
wikitox:2.1.11.4.1_anticholinergics [2024/07/22 20:35] – kharris | wikitox:2.1.11.4.1_anticholinergics [2025/02/24 21:14] (current) – kharris | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | Link to 2.1.11.4.1 [[: | + | ====== |
- | Link to [[: | + | |
- | < | + | |
- | + | ||
- | ---- | + | |
===== Introduction ===== | ===== Introduction ===== | ||
- | Anticholinergic toxicity, to varying degrees, is seen relatively frequently in toxicology patients. The main clinical challenge is the safe management of the delirium which occurs due to ventra | + | Anticholinergic toxicity, to varying degrees, is seen relatively frequently in toxicology patients. The main clinical challenge is the safe management of the delirium which occurs due to central |
The mainstay of treatment is supportive care, whilst time is allowed for the toxicity to resolve; however, patients frequently require sedation and antidotal therapy with physostigmine/ | The mainstay of treatment is supportive care, whilst time is allowed for the toxicity to resolve; however, patients frequently require sedation and antidotal therapy with physostigmine/ | ||
Line 15: | Line 11: | ||
===== Anticholinergic drugs ===== | ===== Anticholinergic drugs ===== | ||
- | Ther are many drugs and natural substances that have anticholinergic effects. | + | There are many drugs and natural substances that have anticholinergic effects. |
**Pure anticholinergic** agents include: | **Pure anticholinergic** agents include: | ||
Line 24: | Line 20: | ||
Drugs with **anticholinergic effects** | Drugs with **anticholinergic effects** | ||
+ | |||
* Antihistamines | * Antihistamines | ||
* Tri-cyclic antidepressants | * Tri-cyclic antidepressants | ||
Line 29: | Line 26: | ||
**Plants** | **Plants** | ||
+ | |||
* // | * // | ||
* //Atropa belladonnna// | * //Atropa belladonnna// | ||
* //Datura stamonium // | * //Datura stamonium // | ||
- | <font inherit/inherit;;# | + | \\ {{: |
+ | |||
+ | {{: | ||
+ | |||
+ | {{: | ||
+ | |||
+ | // | ||
---- | ---- | ||
===== Mechanism of Toxic Effects ===== | ===== Mechanism of Toxic Effects ===== | ||
+ | |||
+ | Agents causing antichoinergic toxicity, do so by blocking the muscarinic acetylcholine receptors in the autonomic and central nervous system. This is a competative blockade, which becomes important when understanding the role of acetylcholinesterase inhibitors in its treatment. | ||
+ | |||
+ | It is the blockade at the central muscarinic-1 (M1) receptors that is most important in driving the delirium. | ||
+ | |||
+ | {{ : | ||
+ | |||
+ | //Synape showing role of acetylcholine, | ||
+ | |||
+ | ---- | ||
+ | |||
+ | ===== Clinical Presentaion ===== | ||
+ | |||
+ | The anticholinergic toxidrome consists of both central and peripheral effects. It is common for the peripheral effects to abate before the central effects, meaning that later in the course of the toxidrome, patients may present with delirium as the main or sole effect. | ||
+ | |||
+ | Most anticholinergic toxicity seen in clinical practive, results from ingestion of agents with multiple receptor effects (as apposed to pure anticholinergics) this may also lead to clouding of the classic toxidrome - a common example being miosis in a patient suffering from an anticholinergice delirium secondary to olanzapine or quetipaine, due to their alpha blocking effects. | ||
+ | |||
+ | * Peripheral effects include - dry skin/mouth, mydriasis, tachycardia, | ||
+ | * Central effects include - confusion, picking movements, agitation, aggression, delirium, sedation, hallucination (mainly visual), seizure (less frequently) | ||
+ | |||
+ | {{ : | ||
+ | |||
+ | //Image depicting the classical anticholinergic effects// | ||
+ | |||
+ | ---- | ||
+ | |||
+ | ===== Management ===== | ||
+ | |||
+ | The amin management challenge is the control of the delirium which is often accompanied by agiation and aggression. Agents that cause anticholinergic delirium often also cause sedation and the delirium may only become apparent once the sedation begins to resolve - in ICU this is a common resason for delayed extbation in this patient group. | ||
+ | |||
+ | **Supportive care** | ||
+ | |||
+ | * Manage patients in a low stimulus environment, | ||
+ | * Urinary retention can be a potent drive of agitation, so seek and relieve by placement of a urinary catheter | ||
+ | * Ensure adequate hydration is maintained | ||
+ | |||
+ | **Antidotal theralpy: Anticholinesterase inhibitors** | ||
+ | |||
+ | Anticholinesterase inhibitors slow the breakdown of acetylcholine in the synaptic cleft, The resultant increase in synaptic acetylcholine levels can outcompete the competitive bloackade of the anticholinergic agent and restore cholinergic tone. | ||
+ | |||
+ | Physostigmine is a parenteral agent that was used frequently in the past with reported high efficacy at controlling anticholinergic delirium. Its use fell out of favour following reports of deterioration and mortality following its use in several tri-cyclic antidepressant overdoses. | ||
+ | |||
+ | On more recent review of these cases, it is evident that these patients were suffering with severe sodium channel blockage and required treatment of this, with alkalinisation and intubation, and it was the lack of providing this that led to their deterioration, | ||
+ | |||
+ | Treatment of anticholinergic delirium with anticholinesterase inhibitors has been shown to both reverse the delirium and control agitation, far better then sedation alone. Their use should be avoided in patients with bronchospasm or bradycardia. Use: | ||
+ | |||
+ | * **Physostigmine 0.5mg (Child: 0.01mg/kg up to 0.5mg)** | ||
+ | The effects often dissipate before the drug toxicity and repeat doses may be needed every 1-2 hours, alternatively, | ||
+ | |||
+ | * Rivastigmine: | ||
+ | |||
+ | Rivastigmine is also available as a transdermal patch, which can be used in those that are not able to take the oral preparation, | ||
+ | |||
+ | These agents are not always easily available, in particular physostigmine is only available via Special Access Scheme (SAS) in Australia. | ||
+ | |||
+ | **Note: Neostigmine and pyridostigmine (which are readily available) do not cross the blood-brain barrier and are of no use in treating anticholinergic delirium. ** | ||
+ | |||
+ | **Sedation** | ||
+ | |||
+ | Sedation may be required as a sole treatment (if physostimine is not available) or as an adjunct to anticholinesterase therapy - particularly in mixed ingestions or ingestion of agents with multiple receptor effects. | ||
+ | |||
+ | In those with mild symptoms, oral sedation may be adequate to contol behaviour. Use: | ||
+ | |||
+ | * **Diazepam 5-20mg** | ||
+ | In those with severe symptoms, particularly when physostigmine is not available, parenteral sedation is often required. Options include: | ||
+ | |||
+ | * **Droperidol 10mg** | ||
+ | * **Midazolam 2.5-5mg** | ||
+ | **Note: Guidelines often advise to avoid droperidol due to its percieved anticholinergic effects worsening the delirium. Droperidol has minimal effects at the central M-1 receptor so this is not a concern. Olanzapine, another drug commonly used in agitated patients, however does have effects at this receptor and should be avoided. ** | ||
+ | |||
+ | ---- | ||
+ | |||
+ | ===== Further Reading ===== | ||
+ | |||
+ | - Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000; | ||
+ | - Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol 2016; | ||
+ | - Chiew AL, Holford AG, Chan BSH, Isoardi KZ. Rivastigmine for the management of anticholinergic delirium. Clin Toxicol (Phila). 2024 Feb; | ||